Oct 23, 2026 · 35 min
Lanifibranor faces a pivotal test in MASH
119 - $IVA: Can Lanifibranor Deliver in Phase 3 MASH?
Inventiva’s Phase 3 program could determine whether lanifibranor can compete in MASH despite weight gain, safety, financing, and dilution concerns.
- 1Lanifibranor’s pan-PPAR approach targets F2/F3 MASH ahead of the pivotal NATiV3 readout.
- 2The competitive field includes approved Rezdiffra and emerging metabolic treatments from major pharmaceutical companies.
- 3Clinical potential must be weighed against weight gain, safety considerations, and Inventiva’s financing and dilution risks.
Don't miss
The episode’s key tension emerges as lanifibranor’s potential efficacy is weighed against weight gain, safety concerns, and Inventiva’s financing risk.
The brief
Inventiva’s lanifibranor is being tested against a central MASH question: can a pan-PPAR agonist improve advanced fibrosis strongly enough to matter in Phase 3?
The episode maps the F2/F3 MASH landscape, including Rezdiffra’s approval and the growing competition from companies pursuing metabolic and liver-disease therapies.
Phase 2 evidence and the NATiV3 design form the core argument, while weight gain and safety considerations complicate the case for lanifibranor.
The analysis extends beyond biology: Inventiva’s financing needs and potential dilution could shape the investment outcome even if the drug performs clinically.
The standout tension is whether lanifibranor’s efficacy opportunity can outweigh its tolerability concerns and the company’s financial risks before the pivotal readout.
What was said on this episode
45 statements · 21 positive · 15 negative · 2 mixed · 7 neutral
Inventiva’s finances cap its potential upside.
“The finances of the company make it such that I think the upside is relatively capped.”
Listen at 0:34
Positive phase-three data could unlock conditional financing for Inventiva.
“if the phase three data is positive”
Listen at 0:44
Negative Phase 3 data would limit Inventiva’s funding options.
“if it's not positive, it really limits some of the funding options for the company.”
Listen at 0:47
Andrew Obenshain’s Bluebird Bio tenure is a negative sign for Inventiva.
“not a great sign of him joining the company”
Listen at 1:43
Inventiva’s Phase 3 readout is the key investment focus.
“we're really just looking at this phase three readout”
Listen at 2:00
MASH-related liver fibrosis is reversible only up to approximately F3.
“It is reversible up to a point, up until you get to F3.”
Listen at 4:05
F4 MASH is difficult to treat.
“once you get to F4, it becomes very difficult.”
Listen at 4:17
Severe MASH fibrosis can lead to cirrhosis, liver failure, and liver cancer.
“the fibrosis becomes so severe that it can lead to cirrhosis, liver failure, even hepatocellular carcinoma.”
Listen at 4:25
F2 and F3 MASH are the most suitable stages for intervention.
“F2 and F3 seem to be the sweet spot”
Listen at 4:51
Approximately 80% of MASH patients have obesity.
“80% of patients with MASH have obesity.”
Listen at 8:47
GLP-1 drugs are taking substantial potential market share from Rezdiffra.
“a large part of the market share that would normally go to ResDifera is being taken by GLP-1s.”
Listen at 9:44
Inventiva could experience a Madrigal-like market-cap increase after positive Phase 3 data.
“Inventiva might have a similar move if it does have positive data for its phase three.”
Listen at 10:19
Inventiva is not attractive as a long-term investment.
“I don't really see Inventiva as a long-term investment.”
Listen at 10:36
PPAR-alpha and PPAR-delta activation tends to improve mitochondrial function and lipid flux.
“targeting alpha and delta tends to help with mitochondrial function as well as lipid flux.”
Listen at 11:22
PPAR-gamma activation tends to improve inflammation and insulin sensitivity.
“targeting gamma tends to help with inflammation, insulin sensitization, and other specific things related to type 2 diabetes.”
Listen at 11:28
PPAR-gamma agonism is associated with weight gain and edema.
“Gamma agonism does tend to have a number of side effects associated with it, specifically weight gain as well as edema.”
Listen at 11:37
The dual-response endpoint combines MASH resolution with fibrosis improvement.
“the dual response is resolution of MASH and improvement of fibrosis.”
Listen at 12:43
Counting patients without final biopsies as nonresponders is a conservative analysis.
“I think it's a relatively conservative way to present the data.”
Listen at 16:23
Lanifibranor’s observed side effects are unlikely to cause major phase-three problems.
“the side effects aren't super likely to be a problem in phase three.”
Listen at 18:01
Allowing GLP-1 use during NATIV-3 may mitigate lanifibranor-related weight gain.
“I think it's actually going to help with any potential weight gain issues.”
Listen at 18:33
Lanifibranor improved insulin resistance, fasting insulin, glucose, and A1C in phase two.
“HOMA-IR goes down quite a bit. Fasting insulin goes down. fasting glucose as well as A1C go down quite well too.”
Listen at 21:18
Lanifibranor’s blood-based fibrosis-marker improvements were less impressive than desired.
“you would have liked to see a greater change in the enhanced liver fibrosis test score”
Listen at 21:41
NATIV-3’s higher F3-patient proportion makes success more difficult for Inventiva.
“more F3 patients. This makes it a little bit more challenging for them”
Listen at 23:07
Lanifibranor will likely hit the dual endpoint or at least one secondary endpoint.
“I think that it's still going to be able to hit. If not the dual response endpoint, at least one of the secondary responses.”
Listen at 25:25
NATIV-3’s placebo response may be at least 15%.
“the placebo is probably going to be at least 15% responders”
Listen at 26:22
“the lanifibrinor groups have to do even better than that.”
Listen at 26:27
A dual-response treatment-placebo delta of at least 11 would be a good NATIV-3 result.
“For the dual response primary, I think a delta of at least 11 is going to be looked at as good.”
Listen at 26:47
A dual-endpoint delta below 11 would require success on another endpoint to support Inventiva.
“if the dual endpoint comes in below 11, I think it would be very helpful if they were able to hit on one of the other two endpoints.”
Listen at 28:14
Lanifibranor has a reasonable chance of Phase 3 success.
“I feel like Lanifibonur has a decent chance”
Listen at 28:28
Some PPAR-gamma agonism may be beneficial if side effects remain manageable.
“having some PPAR gamma agonism can be very beneficial as long as the side effects don't get too out of hand.”
Listen at 30:06
Lanifibranor’s balanced PPAR activity may drive its MASH efficacy.
“I think the lanofibonor balancing the three isoforms of PPAR is what's going to be the special sauce”
Listen at 30:13
Inventiva trades near $3.50 per share at an $850 million market capitalization.
“The price now is about $3.50 a share, giving them a market cap of $850 million.”
Listen at 30:38
Exercising T3 warrants would increase Inventiva’s diluted shares from 313 million to 390 million.
“This would increase the fully diluted share count from 313 million to 390.”
Listen at 31:36
Positive Phase 3 results would enable Inventiva to borrow another €55 million.
“if they are successful there, they're going to be able to borrow another 55 million euros.”
Listen at 31:56
Inventiva’s debt and dilution make it unattractive as a long-term investment.
“There's a lot of debt going on. There's a lot of dilution going on, which I don't love as a long-term investor.”
Listen at 32:03
Positive NATIV-3 results and warrant exercise could give Inventiva access to about $400 million.
“if native three is positive, and all the warrants are exercised, the amount of cash they're going to have access to is going to be about $400 million.”
Listen at 32:15
At $5 per share, Inventiva’s market capitalization would be about $2 billion.
“if the company, say, goes to $5 a share, the market cap will be about $2 billion”
Listen at 32:33
Inventiva’s dilution would limit upside even if its market cap tripled like Madrigal’s.
“If we imagine that a similar move happens from Inventiva that Magical did, where it goes from about a $1 billion market cap to a $3 billion market cap, the dilution is such that it's going to limit the upside here.”
Listen at 32:42
Inventiva’s stock could reach approximately $6.50 in a best-case outcome.
“If it's a blue sky outcome and everything goes well, I see the stock going to about $6.50 a share.”
Listen at 32:58
Inventiva’s stock could fall below cash value if the trial fails.
“If things don't go well, I could easily see it go to below cash”
Listen at 33:06
Inventiva has a good chance of hitting the endpoint and approaching $6 per share.
“I think there's a good chance that it does hit the endpoint and that we do see closer to six dollars a share.”
Listen at 33:22
The speaker recommends taking only a modest Inventiva position.
“I'm going to take a modest position”
Listen at 33:42
Inventiva’s stock will probably decline if the primary endpoint fails despite secondary success.
“if the primary endpoint fails but one of the two secondary endpoints are a success the stock is probably going to sell off”
Listen at 33:52
Secondary-endpoint success could leave Inventiva with a chance of FDA approval.
“there is going to be a chance that they get FDA approval if one of the two secondaries does end up hitting.”
Listen at 34:02
Matt assesses Inventiva’s trial as having a high chance of success.
“I do see that as a high chance of success, though.”
Listen at 34:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.